EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing
Funding accelerates development of late-stage cancer therapies, pipeline expansion and business growth
Syndicate includes all Series A investors, preeminent life science and generalist funds, and market-leading health systems and payers
More info >> |